Endometrial Carcinoma Clinical Trials in New York, New York

5 studies are recruiting for endometrial carcinoma in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

   This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta [TM]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo [TM]) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial cancer. Tras…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Mount Sinai Chelsea, New York, New York

   Locations

   414 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05256225 on ClinicalTrials.gov

2. ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

   The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demonstrate clinical validity for rec…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Icahn School of Medicine at Mount Sinai, New York, New York

   Locations

   57 in total

   Run by

   Guardant Health, Inc.

   See if you can join NCT05059444 on ClinicalTrials.gov

3. Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

   This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interferes with the binding of beta-catenin to TBL1, which may hel…

   Stage

   Phase 1

   Ages

   1 to 30

   Site

   NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York

   Locations

   21 in total

   Run by

   Children's Oncology Group

   See if you can join NCT04851119 on ClinicalTrials.gov

4. FOG-001 in Locally Advanced or Metastatic Solid Tumors

   The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center, New York, New York

   Locations

   33 in total

   Run by

   Parabilis Medicines, Inc.

   See if you can join NCT05919264 on ClinicalTrials.gov

5. A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer

   The purpose of this study is to find out whether short-course radiation therapy (1 week instead of the usual 5 weeks) with chemotherapy (carboplatin and paclitaxel) is practical (feasible), meaning that most participants are able to complete the treatment schedule.

   Stage

   EARLY_Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center, New York, New York

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT05691010 on ClinicalTrials.gov